TGFB1 and idiopathic pulmonary fibrosis: TGF-β1 is probably the most potent profibrotic factor, and downregulation of the TGF-β pathway is an attractive target for IPF therapy, including GC1008, GSK3008348, and BG00011, which are currently undergoing clinical trials (Mora et al., 2017).